Version 1
: Received: 27 May 2022 / Approved: 7 June 2022 / Online: 7 June 2022 (09:00:26 CEST)
How to cite:
Brian, C.; Makrinos, D.; Burke, H.; Bree, D.; Haridas, R.; Tonkiss, I.; Bartsch, Y.; Alter, G.; Malley, R.; Besin, G. Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (Maps) Sars Cov-2 Vaccine. Preprints2022, 2022060098 (doi: 10.20944/preprints202206.0098.v1).
Brian, C.; Makrinos, D.; Burke, H.; Bree, D.; Haridas, R.; Tonkiss, I.; Bartsch, Y.; Alter, G.; Malley, R.; Besin, G. Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (Maps) Sars Cov-2 Vaccine. Preprints 2022, 2022060098 (doi: 10.20944/preprints202206.0098.v1).
Cite as:
Brian, C.; Makrinos, D.; Burke, H.; Bree, D.; Haridas, R.; Tonkiss, I.; Bartsch, Y.; Alter, G.; Malley, R.; Besin, G. Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (Maps) Sars Cov-2 Vaccine. Preprints2022, 2022060098 (doi: 10.20944/preprints202206.0098.v1).
Brian, C.; Makrinos, D.; Burke, H.; Bree, D.; Haridas, R.; Tonkiss, I.; Bartsch, Y.; Alter, G.; Malley, R.; Besin, G. Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (Maps) Sars Cov-2 Vaccine. Preprints 2022, 2022060098 (doi: 10.20944/preprints202206.0098.v1).
Abstract
Despite the remarkable success of SARS CoV-2 vaccines, the rise of variants, some of which are more resistant to the effects of vaccination, highlights the potential need for additional COVID-19 vaccines. We used the Multiple Antigen Presenting System (MAPS) technology, in which proteins are presented on a polysaccharide polymer to induce antibody, Th1, Th17 and CD8+ T cell responses, to engineer a novel vaccine targeting SARS CoV-2. This vaccine contains a fragment of the spike (S) protein receptor-binding domain (RBD) sequence of the original D614G strain and was used to immunize nonhuman primates (NHP) for assessment of immunological responses and protection against SARS CoV-2 challenge. The SARS CoV-2 MAPS vaccine generated robust neutralizing antibodies as well as Th1, Th17 and cytotoxic CD8 T-cell responses in NHPs. Furthermore, MAPS-immunized NHPs had significantly lower viral loads in the nasopharynx and lung compared to control animals. Taken together, these findings support the use of the MAPS platform to make a SARS CoV-2 vaccine. The nature of the platform also could enable its use for the inclusion of different variants in a single vaccine.
Keywords
SARS CoV-2 Vaccine; MAPS
Subject
LIFE SCIENCES, Immunology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
